Combined Anabolic Therapy

Combined Anabolic Therapy Study

In this research study the study investigators want to learn more about the effect of two different FDA-approved medication regimens in the treatment of postmenopausal osteoporosis.

Inclusion Criteria:

• women aged 45+
• postmenopausal
• osteoporotic with high risk of fracture

Exclusion Criteria:

• no significant previous use of bone health modifying treatments
• known congenital or acquired bone disease other than osteoporosis
• significant renal disease, liver disease, cardiopulmonary disease, or psychiatric disease
• abnormal calcium or parathyroid hormone level
• serum vitamin D <20 ng/dL
• anemia (hematocrit <32%)
• history of malignancy (except non-melanoma skin carcinoma)
• excessive alcohol use or substance abuse
• known contraindications to romosozumab or teriparatide